< > J70 - Vaccine

Organisation International Society for Vaccines
Publisher Elsevier Science Ltd., Oxford, UK
ISSN 0264-410X

Specific Chapter/Section References

Ref. Year Authors Title Vol. Pages
J70.3.w1 1985 Campbell, C.H. Immunogenicity of bluetongue virus inactivated by gamma irradiation 3 401-406
J70.4.w1 1986 Xin, X. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine 4 212-216
J70.6.w1 1988 Brown, F. Use of peptides for immunization against foot-and-mouth disease 6 180-182
J70.6.w2 1988 Kitching, R.P., Rendle, R. & Ferris, N.P. Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease virus 6 403-408
J70.6.w3 1988 Yamanishi, K., Tanishita, O., Tamura, M., Asada, H., Kondo, K., Takagim M., Yoshida, I., Konobe, T. & Fukai K. Development of inactivated vaccine against virus causing haemorrhagic fever with renal
syndrome
6 278-282
J70.9.w1 1991 Barteling, S.J. & Vreeswijk, J. Developments in foot-and-mouth disease vaccines 9 75-88
J70.10.w1 1992 Pay, T.W.F. & Hingley, P.J. Foot and mouth disease vaccine potency tests in cattle: the interrelationship of antigen dose, serum neutralising antibody response and protection from challenge 10 699-706
J70.10.w2 1992 Pay, T.W.F. & Hingley, P.J A potency test method for foot and mouth disease vaccine based on the serum neutralising antibody response produced in cattle 10 707-713
J70.10.w3 1992 Brown, F. New approaches to vaccination against foot-and-mouth disease 10 1022-1026
J70.10.w4 1992 Schmaljohn, C.S., Hasty, S.E. & Dalrymple, J.M. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome 10 10-13
J70.10.w5 1992 Roy, P., French, T. & Erasmus, B.J. Protective efficacy of virus-like particles for bluetongue disease 10 28-32
J70.11.w1 1993 Grubman, M.J., Lewis, S.A. & Morgan, D.O. Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems 11 825-829
J70.11.w2 1993 Nair, S.P. & Sen, A.K. A comparative study of the immune responses of sheep against foot-and-mouth disease virus types Asia-1 and O PEG-concentrated aluminium hydroxide gel and oil-adjuvanted vaccines 11 782-786
J70.12.w1 1994 Doel, T.R., Williams, L. & Barnett, P.V. Emergency vaccination against foot-and-mouth disease: Rate of development of immunity and its implications for the carrier state 12 592-600
J70.12.w2 1994 Lafay, F., Bénéjean, J., Tuffereau, C., Flamand, A. & Coulon, P. Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern 12 317-320
J70.13.w1 1995 Fulop, M., Manchee, R. & Titball, R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia 13 1220-1225
J70.14.w1 1996 Osorio, J.E., Hubbard, G.B., Soike, K.F., Girard, M., van der Werf, S., Moulin, J.C. & Palmenberg, A.C. Protection of non-murine mammals against encephalomyocarditis virus using a genetically engineered Mengo virus 14 155-161
J70.15.w1 1997 Lowrie, D.B., Silva, C.L., Colston, M.J., Ragno, S. & Tascon, R.E. Protection against tuberculosis by a plasmid DNA vaccine 15 834-838
J70.16.w1 1998 Mackay, D.K.J., Forsyth, M.A., Davies, P.R., Berlinzani, A., Belsham, G.J., Flint, M. & Ryan, M.D. Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA 16 446-459
J70.16.w2 1998 Salt, J.S., Barnett, P.V., Dani, P. & Williams, L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission 16 746-754
J70.16.w3 1998 Hunter, P., Swanepoel, S. P., Esterhuysen, J. J., Raath, J. P., Bengis, R. G. & Van der Lugt, J. J. The efficacy of an experimental oil-adjuvanted encephalomyocarditis vaccine in elephants, mice and pigs. 16 55-61
J70.16.w4 1998 Ulrich, R., Lundkvist, A., Meisel, H., Koletzki, D., Sjölander, K.B., Gelderblom, H.R., Borisova, G., Schnitzler, P., Darai, G. & Krüger, D.H. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model 16 272-280
J70.17.w1 1999 Leforban, Y. Preventative measures against foot-and-mouth disease in Europe in recent years 17 1755-1759
J70.17.w2 1999 Shen, F., Chen, P.D., Walfield, A.M., Ye, J., House, J., Brown, F. & Wang, C.Y. Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA 17 3039-3049
J70.17.w3 1999 Doel, T.R. Optimisation of the immune response to foot-and-mouth disease vaccines 17 1767-1771
J70.17.w4 1999 Cox, S.J., Barnett, P.V., Dani, P. & Salt, J.S. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission 17 1858-1868
J70.17.w5 1999 Garland, A.J.M. Vital elements for the successful control of foot-and-mouth disease by vaccination 17 1760-1766
J70.17.w6 1999 Cho, H.-W. & Howard, C.R. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax®) 17 2569-2575
J70.19.w1 2000 Torres, J.M., Ramírez, M.A., Morales, M., Bárcena, J., Vázquez, B., Espuńa, E., Pagčs-Manté, A. & Sánchez-Vizcaíno, J.M. Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease 19 174-182
J70.19.w2 2001 Torres, J.M., Sánchez, C., Ramírez, M.A., Morales, M., Bárcena, J., Ferrer, J., Espuńa, E., Pagčs-Manté, A. & Sánchez-Vizcaíno, J.M. First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease 19 4536-4543
J70.19.w3 2001 Fulop, M., Mastroeni, P., Green, M. & Titball, R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis 19 4465-4472
J70.19.w4 2001 Bucht, G., Sjölander, K.B., Eriksson, S., Lindgren, L., Lundkvist, A. & Elgh, F. Modifying the cellular transport of DNA-based vaccines alters the immune response to
hantavirus nucleocapsid protein
19 3820-3829
J70.19.w5 2000 van Gennip, H.G., van Rijn, P.A., Widjojoatmodjo, M.N., de Smit, A.J. & Moormann, R.J.
 
Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response 19 447-459
J70.19.w6 2000 Vordermeier, H.M., Cockle, P.J., Whelan, A.O., Rhodes, S., Chambers, M.A., Clifford, D., Huygen, K., Tascon, R., Lowrie, D., Colston, M.J. & Hewinson, R.G. Effective DNA vaccination of cattle with the mycobacterial antigens MPB83 and MPB70 does not compromise the specificity of the comparative intradermal tuberculin skin test 19 1246-1255
J70.20.w1 2002 Monath, T.P., McCarthy, K., Bedford, P., Johnson, C.T., Nichols, R., Yoksan, S., Marchesani, R., Knauber, M., Wells, K.H., Arroyo, J. & Guirakhoo, F. Clinical proof of principle for ChimeriVaxTM: recombinant live, attenuated vaccines against flavivirus infections. 20 1004-1018
J70.20.w2 2002 Barnett, P.V., Cox, S.J., Aggarwal, N., Gerber, H., & McCullough, K.C. Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine. 20 3197-3208
J70.20.w3 2002 Moraes, M.P., Mayr, G.A., Mason, P.W. & Grubman, M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24 20 1631-1639
J70.20.w4 2002 Wong, H.T., Cheng, S.C., Sin, F.W., Chan, E.W., Sheng, Z.T. & Xie, Y. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2 20 2641-2647
J70.20.w5 2002 van Gennip, H.G., Bouma, A., van Rijn, P.A., Widjojoatmodjo, M.N. & Moormann, R.J. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV 20 1544 - 1556
J70.20.w6 2002 Zhang, M., Emerson, S.U., Nguyen, H., Engle, R., Govindarajan, S., Blackwelder, W.C., Gerin, J. & Purcell RH. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques 20 3285-3291
J70.21.w1 2003 Choi, Y., Ahn, C.J., Seong, K.M., Jung, M.Y. &, Ahn, B.Y. Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells 21 1867-1873
J70.21.w2 2003 Waters, W.R., Palmer, M.V., Olsen, S.C., Sacco, R.E. & Whipple, D.L. Immune responses of elk to Mycobacterium bovis bacillus Calmette Guerin vaccination 21 1518-1526
J70.22.w1 2003 Moraes, M.P., Chinsangaram, J., Brum, M.C. & Grubman, M.J.  Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine 22 268-279
J70.22.w3 2004 Barnett, P.V., Keel, P., Reid, S., Armstrong, R.M., Statham, R.J., Voyce, C., Aggarwal, N. & Cox, S.J.  Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the "carrier" state in sheep 22 1221-1232
J70.22.w4 2004 Klingström, J., Maljkovic, I., Zuber, B., Rollman, E., Kjerrström, A. & Lundkvist, A. Vaccination of C57/BL6 mice with Dobrava hantavirus nucleocapsid protein in Freund's adjuvant induced partial protection against challenge 22 4029-4034
J70.22.w5 2004 Li, T.C., Suzaki, Y., Ami, Y., Dhole, T.N., Miyamura, T. & Takeda, N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles 22 370-377
J70.22.w6 2004 Aldwell, F.E., Keen, D.L., Parlane, N.A., Skinner, M.A., de Lisle, G.W. & Buddle, B.M. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums 22 70-76
J70.23.w1 2005 Parida, S., Cox, S.J., Reid, S.M., Hamblin, P., Barnett, P.V., Inoue, T., Anderson, J. & Paton, D.J. The application of new techniques to the improved detection of persistently infected cattle after vaccination and contact exposure to foot-and-mouth disease 23 5186-5195
J70.23.w2 2005 Orsel, K., Dekker, A., Bouma, A., Stegeman, J.A. & de Jong, M.C.M. Vaccination against foot and mouth disease reduces virus transmission in groups of calves 23 4887-4894
J70.23.w3 2005 Cox, S.J., Voyce, C., Parida, S., Reid, S.M., Hamblin, P.A., Hutchings, G., Paton, D.J. & Barnett, P.V. Protection against direct-contact challenge following emergency FMD vaccination of cattle and the effect on virus excretion from the oropharynx 23 1106-1113
J70.23.w4 2005 Golde, W.T., Pacheco, J.M., Duque, H., Doel, T., Penfold, B., Ferman, G.S., Gregg, D.R. & Rodriguez, L.L.  Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response 23 5775-5782
J70.23.w5 2005 Karaca, K., Bowen, R., Austgen, L.E., Teehee, M., Siger, L., Grosenbaugh, D., Loosemore, L., Audonnt, J.-C., Nordgren, R. & Minke, J.M. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge 23 3808-3813
J70.23.w5 2005 Samina, I., Khinich, Y., Simanov, M. & Malkinson, M. An inactivated West Nile virus vaccine for domestic geese - efficacy study and a summary of 4 years of field application 23 4955-4958
J70.23.w6 2005 Conlan, J,W., Shen, H., KuoLee, R., Zhao, X. & Chen, W. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism 23 2477-2485
J70.23.w7 2005 Geldmacher, A., Skrastina, D., Borisova, G., Petrovskis, I., Krüger, D.H., Pumpens, P. & Ulrich, R. A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies 23 3973-3983
J70.23.w8 2005 Li, S.W., Zhang, J., Li, Y.M., Ou, S.H., Huang, G.Y., He, Z.Q., Ge, S.X., Xian, Y.L., Pang, S.Q., Ng, M.H. & Xia, N.S. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates 23 2893-2901
J70.23.w9 2005 Veronesi, E., Hamblin, C. & Mellor, P.S. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae) 23 5509-5516
J70.23.w10 2005 Arricau-Bouvery, N., Souriau, A., Bodier, C., Dufour, P., Rousset, E. & Rodolakis, A. Effect of vaccination with phase I and phase II Coxiella burnetii vaccines in pregnant goats 23 4394-4402
J70.23.w11 2005 Buddle, B.M., Aldwell, F.E., Skinner, M.A., de Lisle, G.W., Denis, M., Vordermeier, H.M., Hewinson, R.G. & Wedlock, D.N. Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis 23 3581-3589
J70.24.w1 2006 Cox, S.J., Voyce, C., Parida, S., Reid, S.M., Hamblin, P.A., Paton, D.J. & Barnett, P.V. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle 24 3184-3190
J70.24.w2 2005 Borrego, B., Fernandez-Pacheco, P., Ganges, L., Domenech, N., Fernandez-Borges, N., Sobrino, F. & Rodriguez, F.  DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses 24 3889-3899
J70.24.w3 2006 Girard, M.P., Osmanov, S.K. & Kieny, M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV) 24 4062-4081
J70.24.w4 2006 Griffin, J.F., Mackintosh, C.G. & Rodgers, C.R. Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis 24 835-845
J70.25.w1 2007 Orsel, K., de Jong, M.C.M., Bouma, A., Stegeman, J.A. & Dekker, A. Foot and mouth disease transmission among vaccinated pigs after exposure to virus shedding pigs 25 6381-6391
J70.25.w2 2007 Orsel, K., Dekker, A., Bouma, A., Stegeman, J.A. & de Jong, M.C.M. Quantification of foot and mouth disease virus excretion and transmission within groups of lambs with and without vaccination 25 2673-2679
J70.25.w3 2007 Orsel, K., de Jong, M.C.M., Bouma, A., Stegeman, J.A. & Dekker, A. The effect of vaccination on foot and mouth disease virus transmission among dairy cows 25 327-335
J70.25.w4 2007 Eble, P.L., Bouma, A, Weerdmeester, K., Stegeman, J.A. & Dekker, A. Serological and mucosal immune responses after vaccination and infection with FMDV in pigs 25 1043-1054
J70.25.w5 2007 Xiao, C., Rajput, Z.I. & Hu, S. Improvement of commercial foot-and-mouth disease vaccine by supplement of Quil A 25 4795-4800
J70.25.w6 2007 Goris, N., Merkelbach-Peters, P., Diev, V.I., Verloo, D., Zakharov, V.M., Kraft, H.-P. & De Clercq, K. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences 25 3373-3379
J70.25.w7 2007 Samina, I., Havenga, M., Koudstaal, W., Khinich, Y., Koldijk, M., Malkinson, M., Simanov, M., Perl, S., Gijsbers, L., Weverling, G.J., Uytdehaag, F. & Goudsmit, J. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine 25 8338-8345
J70.25.w8 2007 KuoLee, R., Harris, G., Conlan, J.W. & Chen, W. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis 25 3781-3791
J70.25.w9 2007 Beer, M., Reimann, I., Hoffmann, B. & Depner, K. Novel marker vaccines against classical swine fever. 25 5665-5670
J70.25.w10 2007 Koenig, P., Lange, E., Reimann, I. & Beer, M. CP7_E2alf: a safe and efficient marker vaccine strain for oral immunisation of wild boar against Classical swine fever virus (CSFV) 25 3391-3399
J70.25.w11 2007 Dong, X-N & Chen, Y-H. Marker vaccine strategies and candidate CSFV marker vaccines 25 205-230
J70.25.w12 2007 Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep 25 672-678
J70.25.w13 2007 Perrin, A., Albina, E., Bréard, E., Sailleau, C., Promé, S., Grillet, C., Kwiatek, O., Russo, P., Thiéry, R., Zientara, S. & Cętre-Sossah, C. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants 25 6774-6783
J70.25.w14 2007 Waters, W.R., Palmer, M.V., Nonnecke, B.J., Thacker, T.C., Scherer, C.F., Estes, D.M., Jacobs, W.R. Jr, Glatman-Freedman, A. & Larsen, M.H. Failure of a Mycobacterium tuberculosis ΔRD1 ΔpanCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis bacille Calmette Guerin 25 7832-7840
J70.25.w15 2007 Khare, S., Hondalus, M.K., Nunes, J., Bloom, B.R. & Adams, L. G. Mycobacterium bovis ΔleuD auxotroph-induced protective immunity against tissue colonization, burden and distribution in cattle intranasally challenged with Mycobacterium bovis Ravenel S 25 1743-1755
J70.25.w16 2007 Palmer, M.V., Thacker, T.C. & Waters, W.R. Vaccination of white-tailed deer (Odocoileus virginianus) with Mycobacterium bovis bacillus Calmette Guerín 25 6589-6597
J70.26.w1 2008 Pasetti, M.F., Cuberos, L., Horn, T.L., Shearer, J.D., Matthews, S.J., House, R.V. &, Sztein, M.B. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes 26 1773-1785
J70.26.w2 2008 Bakshi, C.S., Malik, M., Mahawar, M., Kirimanjeswara, G.S., Hazlett, K.R., Palmer, L.E., Furie, M.B., Singh, R., Melendez, J.A., Sellati, T.J. & Metzger, D.W. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
26 5276-5288
J70.26.w3 2008 Spik, K.W., Badger, C., Mathiessen, I., Tjelle, T., Hooper, J.W. & Schmaljohn, C. Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters 26 5177-5181
J70.27.w1 2009 Jia, Q., Lee, B.Y., Clemens, D.L., Bowen, R.A. & Horwitz, M.A. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis 27 1216-1229
J70.27.w2 2009 El Sahly, H.M., Atmar, R.L., Patel, S.M., Wells, J.M., Cate, T., Ho, M., Guo, K., Pasetti, M.F., Lewis, D.E., Sztein, M.B. & Keitel, W.A. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.
27 4905-4911
J70.27.w3 2009 Gregory SH, Mott S, Phung J, Lee J, Moise L, McMurry JA, Martin W, De Groot AS. Epitope-based vaccination against pneumonic tularemia 27 5299-5306
J70.27.w4 2009 Cong, Y., Yu, J.J., Guentzel, M.N., Berton, M.T., Seshu, J., Klose, K.E. & Arulanandam, B.P. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge 27 5554-5561
J70.27.w5 2009 Schmaljohn, C. Vaccines for hantaviruses 27 D61-D64
J70.27.w6 2009 Zhang, J., Liu, C.B., Li, R.C., Li, Y.M., Zheng, Y.J., Li, Y.P., Luo, D., Pan, B.B., Nong, Y., Ge, S.X., Xiong, J.H., Shih, J.W., Ng, M.H. & Xia, N.S. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine
 
27 1869-1874
J70.27.w7 2009 Hamers, C., Rehbein, S., Hudelet, P., Blanchet, M., Lapostolle, B., Cariou, C., Duboeuf, M.& Goutebroze, S. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep 27 2789-2793
J70.27.w8 2009 Eschbaumer, M., Hoffmann, B., König, P., Teifke, J.P., Gethmann, J.M., Conraths, F.J., Probst, C., Mettenleiter, T.C. & Beer, M. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep 27 4169-4175
J70.27.w9 2009 Oura, C.A., Wood, J.L., Sanders, A.J., Bin-Tarif, A., Henstock, M., Edwards, L., Floyd, T., Simmons, H. & Batten, C.A. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep 27 7326-7330
J70.27.w10 2009 Gethmann, J., Hüttner, K., Heyne, H., Probst, C., Ziller, M., Beer, M., Hoffmann, B., Mettenleiter, T.C. & Conraths, F.J. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions
 
27 4118-4126
J70.27.w11 2009 Ballesteros, C., Garrido, J.M., Vicente, J., Romero, B., Galindo, R.C., Minguijón, E., Villar, M., Martín-Hernando, M.P., Sevilla, I., Juste, R., Aranaz, A., de la Fuente, J. & Gortázar, C. First data on Eurasian wild boar response to oral immunization with BCG and challenge with a Mycobacterium bovis field strain
 
27 6662-6668
J70.27.w12 2009 Lesellier, S., Corner, L., Costello, E., Lyashchenko, K., Greenwald, R., Esfandiari, J., Singh, M., Hewinson, R.G., Chambers, M. & Gormley, E. Immunological responses and protective immunity in BCG vaccinated badgers following endobronchial infection with Mycobacterium bovis 27 402-409
J70.27.w13 2009 Waters, W.R., Palmer, M.V., Nonnecke, B.J., Thacker, T.C., Scherer, C.F., Estes, D.M., Hewinson, R.G., Vordermeier, H.M., Barnes, S.W., Federe, G.C., Walker, J.R., Glynne, R.J., Hsu, T., Weinrick, B., Biermann, K., Larsen, M.H. & Jacobs, W.R. Jr. Efficacy and immunogenicity of Mycobacterium bovis ΔRD1 against aerosol M. bovis infection in neonatal calves

 
27 1201-1209
J70.28.w1 2010 Eschbaumer, M., Wäckerlin, R., Hoffmann, B. & Beer, M. Re: Detection of bluetongue virus genome after vaccination with an inactivated vaccine 28 881-882
J70.28.w2 2010 Wäckerlin R, Eschbaumer M, König P, Hoffmann B, Beer M. Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle 28 4348-4355
J70.28.w3 2010 Veronesi, E., Darpel, K.E., Hamblin, C., Carpenter, S., Takamatsu, H.H., Anthony, S.J., Elliott, H., Mertens, P.P. & Mellor, P.S. Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4 28 1397-1403
J70.28.w4 2010 Stewart, M., Bhatia, Y., Athmaran, T.N., Noad, R., Gastaldi, C., Dubois, E., Russo, P., Thiéry, R., Sailleau, C., Bréard, E., Zientara, S. & Roy, P. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus 28 3047-3054
J70.28.w5 2010 Corner, L.A., Costello, E., O'Meara, D., Lesellier, S., Aldwell, F.E., Singh, M., Hewinson, R.G., Chambers, M.A., Gormley, E. Oral vaccination of badgers (Meles meles) with BCG and protective immunity against endobronchial challenge with Mycobacterium bovis 28 6265-6272
J70.X.w1 / J70.29.w1 2011 Hickey, A.J., Hazlett, K.R., Kirimanjeswara, G.S. & Metzger, D.W. Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia 29 6941-6947
J70.29.w2 2011 Bréard, E., Belbis, G., Hamers, C., Moulin, V., Lilin, T., Moreau, F., Millemann, Y., Montange, C., Sailleau, C., Durand, B., Desprat, A., Viarouge, C., Hoffmann, B., de Smit, H., Goutebroze, S., Hudelet, P. & Zientara, S. Evaluation of humeral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats 29 2495-2502
J70.29.w3 2011 Lesellier, S., Palmer, S., Gowtage-Sequiera, S., Ashford, R., Dalley, D., Davé, D., Weyer, U., Salguero, F.J., Nunez, A., Crawshaw, T., Corner, L.A., Hewinson, R.G. & Chambers, M.A. Protection of Eurasian badgers (Meles meles) from tuberculosis after intra-muscular vaccination with different doses of BCG 29 3782-3790
J70.30.w1 2012 Boudreau, E.F., Josleyn, M., Ullman, D., Fisher, D., Dalrymple, L., Sellers-Myers, K., Loudon, P., Rusnak, J., Rivard, R., Schmaljohn, C. & Hooper, J.W. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for
hemorrhagic fever with renal syndrome
30 1951-1958
J70.30.w2 2012 Lin, G.J., Deng, M.C., Chen, Z.W., Liu, T.Y., Wu, C.W., Cheng, C.Y., Chien, M.S. & Huang, C. Yeast expressed classical swine fever E2 subunit vaccine candidate provides complete protection against lethal challenge infection and prevents horizontal virus transmission 30 2336-2341
J70.30.w3 2012 van der Sluijs, M.T., Schroer-Joosten, D.P., Fid-Fourkour, A., Vrijenhoek, M.P., Debyser, I., Gregg, D.A., Dufe, D.M., Moulin, V., Moormann, R.J. & de Smit, A.J. Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers 30 647-655
J70.30.w4 2012 Moulin, V., Noordegraaf, C.V., Makoschey, B., van der Sluijs, M., Veronesi, E., Darpel, K., Mertens, P.P. & de Smit, H. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine 30 2228-2235
J70.30.w5 2012 Stewart, M., Dovas, C.I., Chatzinasiou, E., Athmaram, T.N., Papanastassopoulou, M., Papadopoulos, O. & Roy, P. Protective efficacy of bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection 30 2131-2139
J70.30.w6 2012 Waters, W.R., Palmer, M.V., Buddle, B.M. & Vordermeier, H.M. Bovine tuberculosis vaccine research: Historical perspectives and recent advances 30 2611-2622
J70.31.w1 2013 Isken, L.D., Kraaij-Dirkzwager, M., Vermeer-de Bondt, P.E., Rümke, H.C., Wijkmans, C., Opstelten, W. & Timen, A. Implementation of a Q fever vaccination program for high-risk patients in the Netherlands 31 2617-2622
J70.31.w2 2013 Tompkins, D.M., Buddle, B.M., Whitford, J., Cross, M.L., Yates, G.F., Lambeth, M.R. & Nugent, G. Sustained protection against tuberculosis conferred to a wildlife host by single dose oral vaccination
 
31 893-899

Return to top of page